ACT Genomics Holdings Company Limited Revenue and Competitors
Estimated Revenue & Valuation
- ACT Genomics Holdings Company Limited's estimated annual revenue is currently $29.7M per year.
- ACT Genomics Holdings Company Limited's estimated revenue per employee is $270,000
Employee Data
- ACT Genomics Holdings Company Limited has 110 Employees.
- ACT Genomics Holdings Company Limited grew their employee count by -5% last year.
ACT Genomics Holdings Company Limited Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $66.2M | 223 | 20% | N/A | N/A |
#2 | $7.3M | 34 | 6% | N/A | N/A |
#3 | $217.7M | 645 | 27% | N/A | N/A |
#4 | $129.6M | 384 | 10% | N/A | N/A |
#5 | $15.1M | 62 | 22% | N/A | N/A |
#6 | $42.8M | 144 | 15% | N/A | N/A |
#7 | $110.8M | 323 | 13% | $117M | N/A |
#8 | $103.2M | 301 | 2% | $440.7K | N/A |
#9 | $107.3M | 318 | 10% | N/A | N/A |
#10 | $46.9M | 158 | 34% | N/A | N/A |
What Is ACT Genomics Holdings Company Limited?
ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings, we are dedicated to turning every cancer patient's genetic information into actionable resolutions. Our NGS platform coupled with sophisticated bioinformatics tools and curated proprietary databases enable us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone. Our clinical services range from cancer prevention, early detection, treatment selection and disease monitoring, ACTDrug®+ ACTOnco®+, ACTImmune™, ACTColon™, ACTBreast™, ACTGastric™, ACTLung™. Our genomic assays, ACTDrug® and ACTOnco®, offer comprehensive cancer genomic profiling and treatment options for patients with cancer; and provide insights to biomarker discovery and patient stratification for clinical trials. Embracing the future of Precision Medicine. ACT Genomics, your best partner http://www.actgenomics.com/en/
keywords:N/A
N/A
Total Funding
110
Number of Employees
$29.7M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ACT Genomics Holdings Company Limited News
... Scherer's group used sequencing because it reveals novel variants and ... PGx data, the information currently has a limited application,...
Other Companies in Taipei
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $45.6M | 114 | 8% | N/A |
#2 | $15.1M | 116 | 9% | N/A |
#3 | $15.1M | 116 | 9% | N/A |
#4 | $25.3M | 125 | 2% | N/A |
#5 | $32.6M | 133 | 9% | N/A |